Literature DB >> 6450639

Intracellular uptake of 7-con-o-methylnogarol and adriamycin by cells in culture and its relationship to cell survival.

B K Bhuyan, J P McGovren, S L Crampton.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6450639

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  13 in total

1.  Evaluation of menogaril in renal cell carcinoma. A Southwest Oncology Group phase II study (8504).

Authors:  R L Stephens; P Goodman; E D Crawford; C F Spicer; B A Lowe; F R Ahmann; R Chapman; R B Natale
Journal:  Invest New Drugs       Date:  1990       Impact factor: 3.850

Review 2.  Anthracycline analogs: the past, present, and future.

Authors:  R B Weiss; G Sarosy; K Clagett-Carr; M Russo; B Leyland-Jones
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  In vitro cytotoxicity of S16020-2, a new olivacine derivative.

Authors:  S Léonce; V Perez; M R Casabianca-Pignede; M Anstett; E Bisagni; A Pierré; G Atassi
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

4.  Menogaril: a new anthracycline agent entering clinical trials.

Authors:  J P McGovren; K G Nelson; M Lassus; J C Cradock; J Plowman; J P Christopher
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

5.  Menogaril in the treatment of malignant mesothelioma: a phase II study.

Authors:  C A Hudis; D P Kelsen
Journal:  Invest New Drugs       Date:  1992-07       Impact factor: 3.850

6.  Phase I clinical and pharmacokinetic study of menogaril (7-con-O-methylnogarol) in previously treated patients with acute leukemia.

Authors:  C Mazurek; J P Dutcher; E L Schwartz; S Garl; L Benson; P H Wiernik
Journal:  Invest New Drugs       Date:  1993-11       Impact factor: 3.850

7.  Synergistic combination of menogarol and melphalan and other two drug combinations.

Authors:  B K Bhuyan; E G Adams; M Johnson; S L Crampton
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

8.  Pharmacokinetics of 7-con-O-methylnogarol in patients with solid tumors.

Authors:  M L Zanette; U Tirelli; R Sorio; D Zadro; F Figoli; S Monfardini; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

9.  Phase II evaluation of menogaril in patients with advanced hypernephroma.

Authors:  H J Long; M D Hauge; T M Therneau; J C Buckner; S Frytak; R G Hahn
Journal:  Invest New Drugs       Date:  1991-08       Impact factor: 3.850

10.  Phase II evaluation of menogaril in patients with advanced cervical carcinoma. A collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic.

Authors:  H J LONG; H S Wieand; J F Foley; R D Niedringhaus; J A Laurie; R F Morton; R M Goldberg; J A Mailliard; G D Malkasian; J H Edmonson
Journal:  Invest New Drugs       Date:  1991-11       Impact factor: 3.850
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.